为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

INK 128 (MLN0128),mTOR抑制剂, 丝氨酸/苏氨酸蛋白激酶 mTOR 抑制剂

规格或纯度: ≥98%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
I128086-5mg
5mg 现货 Stock Image
I128086-25mg
25mg 现货 Stock Image
I128086-100mg
100mg 现货 Stock Image

基本描述

英文别名 Sapanisertib|1224844-38-5|INK-128|MLN0128|INK 128|INK128|TAK-228|MLN-0128|5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine|INK 128 (MLN0128)|Sapanisertib (MLN0128)|UNII-JGH0DF1U03|JGH0DF1U03|CB-228|3-(2-Amino-5-benzoxazolyl)-
规格或纯度 ≥98%
英文名称 INK 128 (MLN0128)
生化机理 INK 128 exhibits an enzymatic inhibition activity against mTOR and more than 100-fold selectivity to PI3K kinases [1]. As TORC1/2 inhibitor, INK 128 inhibits both the phosphorylation of S6 and 4EBP1, the downstream substrates of TORC1, and selectively inhibits AKT phosphorylation at Ser473, the downstream substrate of TORC2. Furthermore, INK 128 also shows potent inhibition effects on cell lines resistant to rapamycin and pan-PI3K inhibitors
储存温度 -20°C储存
运输条件 超低温冰袋运输
备注 5mg卖完停产,不再备货
产品介绍

INK 128是高活性mTOR抑制剂,IC50为1 nM,比对其它I型PI3K亚型的抑制性高200倍。A potent and selective TORC1/2 inhibitor

INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin).
A potent and selective TORC1/2 inhibitor

产品属性

ALogP 1.7

名称和标识符

IUPAC Name 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
INCHI InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
InChi Key GYLDXIAOMVERTK-UHFFFAOYSA-N
Canonical SMILES CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N
Isomeric SMILES CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N
PubChem CID 45375953
分子量 309.33

化学和物理性质

溶解性 DMSO

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

相关文档

质检报告COA

请输入批号:


产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS.  (2009)  mTOR Mediated Anti-Cancer Drug Discovery..  Drug Discov Today Ther Strateg,  (2):  (47-55).  [PMID:20622997]
2. Schenone S, Brullo C, Musumeci F, Radi M, Botta M.  (2011)  ATP-competitive inhibitors of mTOR: an update..  Curr Med Chem,  18  (20):  (2995-3014).  [PMID:21651476]
3. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ et al..  (2012)  The translational landscape of mTOR signalling steers cancer initiation and metastasis..  Nature,  485  (7396):  (55-61).  [PMID:22367541]
4. Arendse LB, Murithi JM, Qahash T, Pasaje CFA, Godoy LC, Dey S, Gibhard L, Ghidelli-Disse S, Drewes G, Bantscheff M et al..  (2022)  The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages..  Sci Transl Med,  14  (667):  (eabo7219).  [PMID:36260689]